Baxter International Inc (NYSE:BAX) has received an average recommendation of “Buy” from the seventeen analysts that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $68.38.

A number of equities research analysts recently commented on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price objective on the stock in a report on Tuesday, October 24th. BMO Capital Markets reaffirmed a “buy” rating and issued a $70.00 target price on shares of Baxter International in a research report on Friday, October 13th. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Morgan Stanley raised their target price on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $60.00 target price on shares of Baxter International in a research report on Tuesday, October 3rd.

In other news, SVP Giuseppe Accogli sold 28,641 shares of Baxter International stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeanne K. Mason sold 33,350 shares of Baxter International stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the transaction, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,061,991 shares of company stock valued at $325,245,035. 0.05% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in shares of Baxter International by 0.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 4,978,139 shares of the medical instruments supplier’s stock valued at $312,378,000 after acquiring an additional 16,523 shares during the period. Bessemer Group Inc. grew its position in shares of Baxter International by 1.4% in the 3rd quarter. Bessemer Group Inc. now owns 4,717,899 shares of the medical instruments supplier’s stock valued at $296,048,000 after acquiring an additional 64,949 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Baxter International by 1.7% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 2,673,665 shares of the medical instruments supplier’s stock valued at $172,880,000 after acquiring an additional 44,117 shares during the period. Parametric Portfolio Associates LLC grew its position in shares of Baxter International by 4.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 1,666,746 shares of the medical instruments supplier’s stock valued at $104,588,000 after acquiring an additional 73,771 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Baxter International by 3.4% in the 3rd quarter. California Public Employees Retirement System now owns 1,450,242 shares of the medical instruments supplier’s stock valued at $91,003,000 after acquiring an additional 47,076 shares during the period. 83.82% of the stock is owned by institutional investors.

Shares of Baxter International (NYSE BAX) opened at $69.20 on Friday. Baxter International has a twelve month low of $45.47 and a twelve month high of $69.65. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. The company has a market cap of $37,830.00, a price-to-earnings ratio of 37.41, a P/E/G ratio of 2.05 and a beta of 0.69.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period last year, the business posted $0.56 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. analysts predict that Baxter International will post 2.43 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is currently 34.59%.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/19/baxter-international-inc-bax-given-average-rating-of-buy-by-brokerages.html.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.